Jiao Qiangqiang, Xiang Li, Chen Yuping
School of Pharmaceutical Sciences, University of South China, Hengyang, Hunan 410001, China.
Hengyang Medical School, University of South China, Hengyang, Hunan 410001, China.
Int J Pharm. 2024 Jun 10;658:124194. doi: 10.1016/j.ijpharm.2024.124194. Epub 2024 May 3.
As a vital energy source for cellular metabolism and tissue survival, the mitochondrion can undergo morphological or positional change and even shuttle between cells in response to various stimuli and energy demands. Multiple human diseases are originated from mitochondrial dysfunction, but the curative succusses by traditional treatments are limited. Mitochondrial transplantation therapy (MTT) is an innovative therapeutic approach that is to deliver the healthy mitochondria either derived from normal cells or reassembled through synthetic biology into the cells and tissues suffering from mitochondrial damages and finally replace their defective mitochondria and restore their function. MTT has already been under investigation in clinical trials for cardiac ischemia-reperfusion injury and given an encouraging performance in animal models of numerous fatal critical diseases including central nervous system disorders, cardiovascular diseases, inflammatory conditions, cancer, renal injury, and pulmonary damage. This review article summarizes the mechanisms and strategies of mitochondrial transfer and the MTT application for types of mitochondrial diseases, and discusses the potential challenge in MTT clinical application, aiming to exhibit the good therapeutic prospects of MTTs in clinics.
作为细胞代谢和组织存活的重要能量来源,线粒体可根据各种刺激和能量需求发生形态或位置变化,甚至在细胞间穿梭。多种人类疾病源于线粒体功能障碍,但传统治疗的疗效有限。线粒体移植疗法(MTT)是一种创新的治疗方法,即将源自正常细胞或通过合成生物学重新组装的健康线粒体输送到遭受线粒体损伤的细胞和组织中,最终替换其有缺陷的线粒体并恢复其功能。MTT已在心脏缺血再灌注损伤的临床试验中进行研究,并在包括中枢神经系统疾病、心血管疾病、炎症性疾病、癌症、肾损伤和肺损伤在内的众多致命重症疾病的动物模型中表现出令人鼓舞的效果。本文综述了线粒体转移的机制和策略以及MTT在各类线粒体疾病中的应用,并讨论了MTT临床应用中的潜在挑战,旨在展示MTT在临床上良好的治疗前景。